NCT02334462View on ClinicalTrials.gov

Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali

PHASE1CompletedINTERVENTIONAL

Enrollment

538

Participants

Timeline

Start Date

January 7, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

October 22, 2018

Conditions

Malaria

Interventions

BIOLOGICAL

Pfs230D1M-EPA/Alhydrogel

BIOLOGICAL

Pfs25M-EPA/Alhydrogel

DRUG

TWINRIX

DRUG

Menactra

Trial Locations (2)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Unknown

Malaria Research and Training Center, Bamako

All Listed Sponsors

collaborator

Rodolphe Merieux Laboratory@@@Bamako, Mali

UNKNOWN

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02334462 - Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali | Biotech Hunter | Biotech Hunter